Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$346.35M$346.35Mderived+4.8% vs Q4 2025 Net Income-$20.15M-$20.15MderivedN/M vs Q4 2025 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$198,212,000+2.7% Operating Incomederived-$23,025,000N/M Operating Cash Flowderived$70,941,000−39.1% Free Cash Flowderived$53,280,000−47.2% Margins · derivedGross margin57.2%−1.2 pt vs Q4 2025
Operating margin-6.6%−28.2 pt vs Q4 2025
Net margin-5.8%−23.4 pt vs Q4 2025
ended Mar 28, 2026 · filed May 20, 2026 · 53 d after period end